Latest Tax Incentives News

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

AdNeo (ASX:AD1) delivered its first positive operating cash flow quarter since its 2025 transformation, driven by strong revenue growth across all divisions and a growing $8m tender pipeline. The company advances its AI-first strategy while managing costs and acquisitions.

Diatreme Resources reported a $745,000 net loss for FY 2025 but strengthened its financial footing through asset sales and an IPO stake. The company’s Northern Silica Project and Cyclone Zircon Project showed significant technical progress, while a major Cape Flattery asset sale aims to streamline operations and unlock funding.

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.

Adslot Ltd achieved positive net operating cash flow in Q3 FY26 while trimming its workforce by nearly a third to sharpen focus on its Symphony and Webfirm units. The company is navigating declining marketplace revenues and preparing for a key contract renewal with Group M.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Bubalus Resources reports encouraging gold intercepts from maiden Avon Plains drilling while streamlining its portfolio to prioritise Victorian assets and critical minerals projects. The company maintains a solid $3 million cash buffer amid cost cuts and plans multiple exploration campaigns in the coming quarters.

Decidr AI Industries Ltd (ASX: DAI) reported a doubling of its annualised revenue run rate to A$8.06 million as of March 2026, alongside the launch of its Decidr Agentic Graph platform and significant expansion of its partner ecosystem.

Advanced Braking Technology Ltd (ASX: ABV) reported a 28% jump in product sales revenue to $6 million for Q3 FY26, driven by strong aftermarket sales and international market traction. The company also advanced certification of its autonomous BRAKEiQ system, targeting FY27 adoption.

Energy Action Limited posted a milestone quarter ending March 2026, delivering positive operating cash flow for the first time in FY26 alongside strong revenue gains and a notable $0.5 million debt repayment. Governance changes add a layer of uncertainty ahead of a scheduled general meeting.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.